EATONTOWN, N.J.--(BUSINESS WIRE)--Flexible Stenting Solutions, Inc. (“FSS”) is pleased to announce
that it is now authorized to CE Mark and market its 6 Fr Reconstrainable
FlexStent® Self-Expanding Stent System in the European Union.
FSS is a leading developer of next-generation peripheral, neurovascular
and biliary stents. This new device combines the advanced FlexStent®
technology with unique reconstrainable stent delivery technology.

“FSS is always patient
focused; we are very excited about this advanced safety feature.”

Reconstrainability enables the physician to fully recapture then
reposition a partially deployed stent. Based on ongoing market research
and physician feedback, FSS believes reconstrainability will be a
powerful tool for optimizing stent placement in challenging vascular
anatomies thereby enhancing overall patient safety. The Reconstrainable
FlexStent® Femoropopliteal Self Expanding Stent System is
indicated for the treatment of symptomatic atherosclerotic disease of
the femoropopliteal arteries. Stent and system sizes include stent
diameters of 5, 6, 7, and 8 mm in lengths of 30 to 200 mm with delivery
system lengths of 80 cm and 120 cm, as originally CE Mark authorized
with the standard delivery system.

FSS intends to apply this novel reconstrainable delivery technology
across its platform of current and future stent products. With the
elegant and user-friendly reconstrainable delivery system, the complete
FlexStent® family of stents can be delivered with the same
simplicity and low force demonstrated by the standard delivery system.
Recapture and secondary deployment of the stent in the reconstrainable
system are both accomplished with equal ease and simplicity.

Janet Burpee, FSS’s CEO, commented, “Our engineers and Chief Operating
Officer, Bradley Beach, have exceeded my expectations in creating this
novel delivery system.” She further stated that “FSS is always patient
focused; we are very excited about this advanced safety feature.”